Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

  title={Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities},
  author={Neus Mart{\'i}nez-Bosch and Alejo Rodriguez-Vida and Nuria Juanpere and Josep Lloreta and Ana Rovira and Joan Albanell and Joaquim Bellmunt and Pilar Navarro},
  journal={Nature Reviews Urology},
Advanced prostate and bladder cancer are two outstanding unmet medical needs for urological oncologists. The high prevalence of these tumours, lack of effective biomarkers and limited effective treatment options highlight the importance of basic research in these diseases. Galectins are a family of β-galactoside-binding proteins that are frequently altered (upregulated or downregulated) in a wide range of tumours and have roles in different stages of tumour development and progression… 

The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

The possible translation of recent results about galectin expression and functions in pancreatic cancer into clinical interventions (i.e., diagnosis, prediction of prognosis and/or therapy) for this fatal disease is discussed.

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

Findings identify Gal-3 as a key molecule and a potential therapeutic target already in the early phases of prostate cancer progression and metastasis.

Caveolin-1 modulation increases efficacy of a galacto-conjugated phthalocyanine in bladder cancer cells resistant to photodynamic therapy.

The data show the potential of ex vivo cultures of bladder cancer, that ideally could mimic the original microenvironment, in screening galacto-PDT agents, and demonstrate that PDT efficacy in bladder cancer depends on the endocytic mechanisms that regulate PS accumulation and internalization in cancer cells.

Comparative Immunohistochemical Study of Galectins 1, 3 and 9 in Ovarian Epithelial Neoplasms

The significant increase in expression of galectin-1 and -3 in the epithelium of non- benign ovarian neoplasms suggests the participation of these galectins in ovarian carcinogenesis.

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificant

Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies

Affinity purified galactose-specific lectins fractions from normal and pathological tissue samples are characterized with different protein composition and they express different effects on cell viability and apoptosis, which depend on the source of lectin fraction.

Galectins as potential therapeutic targets in STIs in the female genital tract

Current knowledge of the involvement of galectins in sexually transmitted infections in the female genital tract is described and novel opportunities to reduce transmission and dissemination of sexually transmitted pathogens using galectin-targeted agents are highlighted.

Post-Translational Modifications That Drive Prostate Cancer Progression

A comprehensive list of proteome-wide and single protein post-translational modifications and their involvement in phenotypic outcomes is presented and current strategies that exploit the potential of post- Translated modifications in prostate cancer therapy are presented.

Functionalized nano-targeted moieties in management of prostate cancer.

This review describes nano-targeting moieties for management of prostate cancer and its cancer stem cells and indicates that current research results are promising and may yield development of next-generation nanoscale theragnostic targeted modalities for prostate cancer treatment.



[Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Though all findings indicate a future significance of galectins as markers of urological malignancies with clinical relevance, more research will be necessary to particularly assess the evolutional-dependent function of galECTins in the process of tumourigenesis.

Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.

Current evidence on both the expression and role of glycans and galectins in prostate cancer is summarized, particularly turning the authors' attention to the angiogenic and metastatic processes.

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer

It is shown for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer and highlights Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.

The role of glycans in the development and progression of prostate cancer

Emerging data on changes in glycosylation have the potential to improve risk stratification and therapeutic strategies in patients with prostate cancer.

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

A dynamically regulated "galectin-specific signature" that accompanies disease evolution in prostate cancer is identified and highlighted, highlighting a major role for Gal-1 as a tractable target for antiangiogenic therapy in advanced stages of the disease.

Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity

Prostate tumors require Gal-1 in lymphocytes to evade immune responses, and this report lays the foundation for an original immunotherapy strategy for prostate cancer.

Galectins in cancer: carcinogenesis, diagnosis and therapy.

The results of a number of studies published over the past decade are condensed to shed some light on the unique role played by the galectin family of proteins in neoplasia, and how this knowledge may alter the approach to cancer diagnosis and therapy in the future.

Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.

Loss of galectin-3 appears to be involved in the carcinogenesis of TCC and to serve as a valuable biological variable to identify a subgroup of Ta bladder cancer patients at high risk for the development of recurrent disease.

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk

Gal1 hierarchically regulates different events implicated in PDA biology including tumor cell proliferation, invasion, angiogenesis, inflammation, and metastasis, highlighting the broad therapeutic potential of Gal1-specific inhibitors, either alone or in combination with other therapeutic modalities.

Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma

Proteomics results were further translated to prognostic markers by analyses of biopsy samples and demonstrated that over-expressions of glutamine synthetase, alcohol dehydrogenase, fatty acid binding protein 4, and toll interacting protein in clinical specimens were all significantly associated with galectin-1 up-regulation.